Dr. Mark Hyman on Function Health & GLP-1 microdosing | E2334

Summary

Dr. Mark Hyman joins Jason Calacanis to discuss Function Health, its $365/year platform for 160+ biomarkers twice yearly, full-body MRI, and early cancer screening. He explains why insulin and continuous glucose monitoring reveal metabolic dysfunction before blood sugar rises. The conversation covers GLP-1 risks and microdosing, wearables, strength training, mental health, and the promise of psychedelic psychiatry.

• Function Health offers 160+ biomarkers twice a year for about $1/day and has collected over 100 million biomarkers.
• Dr. Hyman says 93% of Americans have some metabolic dysfunction and insulin is rarely checked despite being a cheap early warning.
• He is positive on continuous glucose monitors, full-body MRI, and early cancer detection such as Galleri.
• He views GLP-1s as useful tools but warns about side effects, muscle loss, and unproven microdosing.
• He frames wearables and AI as part of a shift to data-driven, preventive healthcare.
• He criticizes overprescription of psychiatric drugs and highlights nutritional/metabolic psychiatry.
• He says psychedelic psychiatry is promising but needs more data and investment before broad adoption.